(20) showed that Ki-67 expression along with IDH1/2 can significantly differentiate prognosis in glioma, with low Ki-67 expression associated with increased IDH1/2 mutation and IDH1/2 mutant patients with low and moderate Ki-67 expression having the best prognosis. This evidence concerns the gene IDH1 and central nervous system cancer.